Investors Urged to Take Action: Aardvark Therapeutics Faces Securities Class Action Lawsuit

Aardvark Therapeutics Faces Legal Challenges

Aardvark Therapeutics, a biopharmaceutical company focused on developing small-molecule therapies, is currently facing serious legal challenges following the filing of a securities class action lawsuit by Hagens Berman Sobol Shapiro LLP. This notable law firm is renowned for its work in representing shareholders and is urging investors affected by the company's initial public offering (IPO) to act promptly.

The lawsuit pertains to individuals who purchased or acquired shares of Aardvark's common stock either as part of the IPO on February 13, 2025, or during the subsequent class period, which lasted until May 14, 2026. The deadline for investors to apply as lead plaintiff is October 13, 2026, an important date for those eligible to participate in the legal proceedings.

The allegations state that Aardvark's management made misleading claims regarding the safety and efficacy of its lead therapeutic candidate, ARD-101, which targets bitter taste receptors. Investors were reportedly not told about the significant safety concerns associated with ARD-101 that arose during clinical trials. More precisely, reports surfaced that there were unexpected cardiac observations at doses above the targeted therapeutic levels, which the company failed to disclose.

Furthermore, the lawsuit highlights a troubling pattern of communication regarding Aardvark’s clinical and regulatory future. As a result of the withheld information, the company’s projections regarding its trial outcomes appeared overly optimistic. The Phase 3 trial, known as the Hunger Elimination or Reduction Objective (HERO) trial, was notably impacted by these misleading statements.

The situation deteriorated significantly when, on February 27, 2026, Aardvark revealed that it would voluntarily pause the HERO trial due to the aforementioned cardiac issues. This revelation sent shockwaves through the investor community, as Aardvark’s stock price plummeted by more than 56% following the announcement. Just a few months later, on May 14, the FDA placed a full clinical hold on Aardvark’s investigational new drug application for ARD-101, further halting all ongoing studies, which led to an additional stock price fall of 32.1%.

Reed Kathrein, a partner at Hagens Berman, stated that the firm is currently investigating these claims to determine if Aardvark misled investors during the development and marketing of ARD-101. Investors who believe they have suffered losses due to these misunderstandings are being asked to come forward to discuss their potential legal rights and recovery options.

The implications of this lawsuit are significant not only for Aardvark and its investors but also serve as a reminder of the importance of transparency in the biotech sector, particularly during clinical trials that can affect both market sentiment and investor stakes alike. Investors are encouraged to take swift action to determine their involvement in the class action and explore their legal recourses.

For those interested in becoming involved, the firm provides contact options, including a dedicated email and phone number, to discuss individual circumstances and secure potential participation in upcoming hearings. Moreover, potential whistleblowers with non-public information regarding Aardvark Therapeutics may also consider contacting the firm to discuss the possibility of aiding the investigation, with the potential for significant rewards under the SEC Whistleblower program.

In conclusion, the legal environment surrounding Aardvark Therapeutics is evolving rapidly, making it crucial for affected investors to stay informed and proactive in protecting their rights and interests in this ongoing situation.